Comparison of high sensitivity troponin I and NT pro BNP as prognostic markers of major adverse cardiac events across spectrum of ischemic heart disease
Keywords:
atherosclerotic cardiovascular disease, coronary artery bypass grafting, chromic stable angina, high sensitivity Troponin IAbstract
Background: In an era of a cardiovascular epidemic an imminent search for highly sensitive and specific markers for prognostication in ischemic heart disease have been sought. This study attempted to assess how high sensitive troponin I and NT pro BNP fare as prognostic markers for major adverse cardiac events across the spectrum of ischemic heart disease and hence estimate cardiovascular risk.Objective: To compare high sensitivity Troponin I and NT pro BNP as prognostic markers of major adverse cardiac events across the spectrum of ischemic heart diseases including SIHD, USA/NSTEMI and STEMI. Methods:112 subjects were chosen across the spectrum of ischemic heart disease with equal number of STEMI, USA/NSTEMI AND SIHD. Patients were recruited after satisfying the inclusion criteria and standard definitions as per recommendations and guidelines. Hs trop I and NT pro BNP values were obtained for all patients apart from other parameters. The patients in the study underwent treatment as per standard recommendations.. RESULTS: Hs Troponin I was a poor prognostic marker of overall/ cardiovascular mortality if the entire study population was taken into context with a P value=0.954 and 0.765 respectively for baseline and third hour values.
Downloads
References
Casagranda I, Lauritano E C. Diagnostic and prognostic significance of high sensitive troponin in chest pain. Eu Rev Med Pharm Sci. 2011; 15: 695-700.
James S, Flodin M, Johnston N, Lindahl B, Venge P. The antibody configurations of cardiac troponin I assays may determine their clinical performance. Clin Chem. 2006; 52: 832–837.
Kurtieva, S. (2021). Adaptation capabilities of functional systems of the body of adolescents with vegetative dystonia syndrome. International Journal of Health & Medical Sciences, 4(1), 129-135. https://doi.org/10.31295/ijhms.v4n1.1622
Louise Cullen, Christian Mueller, William Parsonage A Et al. Validation of HighSensitivity Troponin I in a 2-Hour Diagnostic Strategy to Assess 30-Day Outcomes in Emergency Department Patients With Possible Acute Coronary Syndrome. J Am coll cardiol. 2013; Vol. 62(No. 14): 1242-1249
Michael Weber, Oscar Bazzino, Jose Navarro Estrada et al. N-Terminal B Type Natriuretic Peptide Assessment Provides Incremental Prognostic Information in Patients with Acute Coronary Syndromes and Normal Troponin T Values Upon Admission. J Am coll cardiol. 2008; Vol. 51(No. 12): 188-1195
Stefan James K, Bertil Lindahl, Agneta Siegbahn et al. N-Terminal Pro–Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients with Unstable Coronary Artery Disease. Circulation. 2003; 108: 275-281
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. International Journal of Health Sciences, 6(1), i-v. https://doi.org/10.53730/ijhs.v6n1.5949
Torbjørn Omlan, Marc Pfeffer A, Scott Solomon D Et al. Prognostic Value of Cardiac Troponin I Measured with a Highly Sensitive Assay in Patients with Stable Coronary Artery Disease. J Am coll cardiol.2013; Vol. 61(No. 12): 1240-1249
Venge P, Lagerqvist B, Diderholm E, et al. Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II sub study). Am J Cardio 2002; 89:1035-41.
Wallace TW, Abdullah SM, Drazner MH, Das SR, Khera A, McGuire DK, Wians F, Sabatin MS, Morrow DA, de Lemos JA: Prevalence and determinants of troponin T elevation in the general population. Circulation 2006;113: 1958–1965.
Wu AH, Jaffe AS. The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing. Am Heart J 2008; 155: 208-214.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
